TMCnet News
PDS Biotech to Participate at BTIG Biotechnology Conference 2022FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that its management will participate in a fireside chat and one-on-one meetings at the BTIG Biotechnology Conference, a hybrid event taking place August 8-9, 2022. To participate in the live event and schedule meetings with management, please contact your BTIG representative. About PDS Biotechnology Our Infectimune™ based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology Corporation. Investor Contacts: Deanne Randolph Rich Cockrell
|